Abstract:BACKGROUND & AIMS:Wnt signaling contributes to the development of colorectal cancer (CRC). We studied interactions between lysine demethylase 4D (KDM4D or JMJD2D) and β-catenin, a mediator of Wnt signaling, in CRC cell lines and the effects on tumor formation in mice.METHODS:We obtained colorectal tumor specimens and surrounding nontumor colon tissues (controls) from patients undergoing surgery in China; levels of JMJD2D were measured by immunohistochemical or immunoblot analysis. JMJD2D expression was knocked down in CRC (CT26, HCT116, and SW480 cells) using small hairpin RNAs, and cells were analyzed with viability, flow cytometry, colony formation, and transwell migration and invasion assays. Cells were also grown as tumor xenografts in nude mice or injected into tail veins or spleens of mice, and metastases were measured. We performed promoter activity, co-immunoprecipitation, and chromatin immunoprecipitation assays. We also performed studies with Apcmin/+ and JMJD2D-knockout mice; these mice were crossed, and colorectal tumor formation in offspring (Apcmin/+Jmjd2d+/+ and Apcmin/+Jmjd2d-/-) was analyzed. JMJD2D-knockout and wild-type (control) mice were given azoxymethane followed by dextran sodium sulfate to induce colitis-associated CRC; some mice were given the JMJD2D inhibitor 5-chloro-8-hydroxyquinoline (5-c-8HQ) or vehicle to examine the effects of 5-c-8HQ on intestinal tumor formation.RESULTS:Levels of JMJD2D were significantly higher in human colorectal tumors than in control tissues and correlated with levels of proliferating cell nuclear antigen. JMJD2D knockdown reduced CRC cell proliferation, migration, and invasion, as well as growth of xenograft tumors and formation of metastases in mice. JMJD2D was required for expression of β-catenin in CRC cell lines; ectopic expression of JMJD2D increased the promoter activities of genes regulated by β-catenin (MYC, CCND1, MMP2, and MMP9). We found that JMJD2D and β-catenin interacted physically and that JMJD2D demethylated H3K9me3 at promoters of β-catenin target genes. JMJD2D-knockout mice developed fewer colitis-associated colorectal tumors than control mice, and their tumor tissues had lower levels of β-catenin, MYC, cyclin D1, and proliferating cell nuclear antigen than tumors from control mice. Apcmin/+Jmjd2d-/- mice developed fewer and smaller colon tumors than Apcmin/+ mice. Mice given 5-c-8HQ developed smaller and fewer colitis-associated tumors, with lower levels of cell proliferation, than mice given vehicle. Apcmin/+ mice given 5-c-8HQ also developed fewer tumors in intestines and colons than mice given vehicle.CONCLUSIONS:Levels of the histone demethylase JMJD2D are increased in human colorectal tumors compared with nontumor colon tissues. JMJD2D interacts with β-catenin to activate transcription of its target genes and promote CRC cell proliferation, migration, and invasion, as well as formation of colorectal tumors in mice.

Histone Demethylase JMJD2B is Required for Tumor Cell Proliferation and Survival and is Overexpressed in Gastric Cancer

JMJD5 Interacts with P53 and Negatively Regulates P53 Function in Control of Cell Cycle and Proliferation.

Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/β-catenin signaling

Elevated JMJD1A is a Novel Predictor for Prognosis and a Potential Therapeutic Target for Gastric Cancer.

JMJD5 Inhibits Lung Cancer Progression by Regulating Glucose Metabolism Through the P53/tigar Pathway

Histone Demethylase JMJD2D Interacts with Β-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice.

Histone Demethylase JMJD2D: A Novel Player in Colorectal and Hepatocellular Cancers

JMJD2B is Required for Helicobacter Pylori-Induced Gastric Carcinogenesis Via Regulating COX-2 Expression.

HIF-1α-induced Histone Demethylase JMJD2B Contributes to the Malignant Phenotype of Colorectal Cancer Cells Via an Epigenetic Mechanism

Histone demethylase Jumonji domain‐containing 1A inhibits proliferation and progression of gastric cancer by upregulating runt‐related transcription factor 3

Role of the Epigenetic Modifier JMJD6 in Tumor Development and Regulation of Immune Response

Histone Demethylase Lysine Demethylase 5B in Development and Cancer

Epigenetic Inactivation of Bcl6b, A Novel Functional Tumour Suppressor for Gastric Cancer, is Associated with Poor Survival

Histoneh3 Demethylase Jmjd2a Promotes Growth Of Liver Cancer Cells Through Up-Regulating Mir372

Epigenetic silencing of promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription of CDKN1A.

Histone Demethylase Jumonji D3 (Jmjd3) As A Tumor Suppressor By Regulating P53 Protein Nuclear Stabilization

Roles of Histone Demethylase JMJD3 in Tumorigenesis

Inflammation-induced JMJD2D Promotes Colitis Recovery and Colon Tumorigenesis by Activating Hedgehog Signaling

Jumonji Domain-Containing Protein 2B Silencing Induces DNA Damage Response Via STAT3 Pathway in Colorectal Cancer.

Demethylase-independent function of JMJD2D as a novel antagonist of p53 to promote Liver Cancer initiation and progression.

The Histone Demethylase RBP2 is Overexpressed in Gastric Cancer and Its Inhibition Triggers Senescence of Cancer Cells.